Dynamic 18 F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer

• Published in: Thoracic cancer 2022-09, Vol.13 (17), p.2524-2531
• Main Authors: Chen, Zhi-Yong, Fu, Rui, Tan, Xiao-Yue, Yan, Li-Xu, Tang, Wen-Fang, Qiu, Zhen-Bin, Qi, Yi-Fan, Li, Yu-Fa, Hou, Qing-Yi, Wu, Yi-Long, Zhong, Wen-Zhao, Jiang, Ben-Yuan
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - drug therapy; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - drug therapy; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography - methods; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies
• ISSN: 1759-7706; 1759-7714
• DOI: 10.1111/1759-7714.14562

Major pathological response (MPR) is a potential surrogate for overall survival. We determined whether the dynamic changes in F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography ( F-FDG PET/CT) were associated with MPR in patients receiving neoadjuvant immunotherapy. Forty-four patients with stage II-III non-small cell lung cancer (NSCLC) who received neoadjuvant immunotherapy and radical surgery were enrolled. Moreover, F-FDG PET/CT scans were performed at baseline and within 1 week before surgery to evaluate the disease. All histological sections were reviewed to assess MPR. The detailed clinical features of the patients were analyzed. The reliability of the clinical variables was assessed in differentiating between MPR and non-MPR using logistic regression. Receiver-operating characteristic (ROC) curve analysis identified the SUVmax changes threshold most associated with MPR. Most of the patients were pathologically diagnosed with squamous cell carcinoma and received anti-PD-1 antibodies plus chemotherapy. The immunotherapy regimens included nivolumab, pembrolizumab, and camrelizumab. MPR was observed in more than half of lesions. Tumors with MPR had a higher decrease in the longest dimension on dynamic PET/CT than those without MPR. Furthermore, the decline in SUVmax was significantly different between MPR and non-MPR diseases, and MPR lesions had a prominent mean reduction in SUVmax. SUVmax reduction was independently associated with MPR in the multivariate regression. On ROC analysis, the threshold of SUVmax decrease in 60% was associated with MPR. Dynamic changes in SUVmax were associated with MPR. The tumors with MPR showed a greater PET/CT response than those without MPR. A SUVmax decrease of more than 60% is more likely to result in an MPR after receiving neoadjuvant immunotherapy.